We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Diagnostics

Image: Smart Stickers are changing the way melanoma is detected (Photo courtesy of DermTech)

Non-Invasive Melanoma Test Ushers in New Era in Skin Cancer Detection

Skin cancer overall is the most common form of cancer with melanoma being the third most common and also the most aggressive form of skin cancer. Now, an innovative test painlessly collect cells from the skin and applies precision genomics to diagnose melanoma accurately and at the earliest curable stage. More...
25 Jan 2023
Image: MetriDx is a diagnostic test for the definitive, early diagnosis and staging of endometriosis (Photo courtesy of Hera Biotech)

World’s First Molecular, Cell-Based Test Offers Non-Surgical Method for Diagnosis and Staging of Endometriosis

Hera Biotech is developing and commercializing the world’s first non-surgical test for the definitive diagnosis and staging of endometriosis. Hera’s breakthrough approach is based on cutting edge, single cell, micro-fluidic analysis to identify endometriosis-specific biological markers, enabling clinicians to definitively diagnose endometriosis regardless of stage with unparalleled accuracy. More...
25 Jan 2023
Image: The new test is designed to measure neutralizing antibodies of the deadly opioid fentanyl (Photo courtesy of AXIM)

Rapid POC Diagnostic Assay Could Detect and Measure Fentanyl Neutralizing Antibodies

AXIM Biotechnologies, Inc. is leveraging its experience in diagnostics and working with neutralizing antibodies to develop a rapid point-of-care diagnostic assay that will detect and measure the levels of fentanyl neutralizing antibodies. More...
23 Jan 2023
Image: The EZ2 Connect MDx is designed for fast automated nucleic acid extraction in IVD workflows (Photo courtesy of QIAGEN)

Molecular Diagnostic Platform for Automated Sample Processing to Help Labs Achieve New Flexibility Level

QIAGEN N.V. (Venlo, Netherlands) has launched EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing available for wide scale use 18 months after it was first made available for research. The EZ2 Connect MDx offers a high degree of automation, enabling labs to purify DNA and RNA from 24 samples in parallel in as less as 30 minutes. More...
23 Jan 2023
Image: A new biosensor can be used to screen for Alzheimer’s and other diseases (Photo courtesy of Pexels)

Early Alzheimer’s Detection Sensor Could Also Diagnose Other Diseases at POC

Currently, screening tests for Alzheimer’s disease involve a questionnaire to determine the individual’s symptoms, brain imaging, or a spinal tap process to test for biomarker proteins in the cerebral spinal fluid. Now, researchers are developing a new biosensor for detecting tumor Necrosis Factor alpha (TNF alpha) that can be used to screen for Alzheimer’s disease and other diseases. More...
23 Jan 2023
First-ever pan-cancer blood-test could predict immune checkpoint inhibitors efficacy and toxicity (Photo courtesy of Pexels)

First-Of-A-Kind Pan-Cancer Blood Test Could Predict Immunotherapy Efficacy and Toxicity

A first-of-a-kind pan-cancer blood test for the prediction of immunotherapy efficacy and toxicity could guide clinicians in patient selection to support the effective use of immune checkpoint inhibitors (ICI), thereby encouraging the use of ICIs in the earlier stages of cancer. More...
20 Jan 2023
A global study has paved the way for the development of the world’s first test to detect diabetics at risk of kidney disease (Photo courtesy of Monash University)

World’s First Test Detects Diabetics at Risk of Kidney Disease before Symptoms Appear

Researchers have identified the genetic markers for people with diabetes who are at a risk of developing kidney disease. This paves the way for the development of a test that could identify adults with Type 1 diabetes who are at a risk of kidney disease before they show any symptoms, enabling the introduction of early-stage interventions by doctors. More...
19 Jan 2023
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Gel Cards
DG Gel Cards


Genetic Testing channel of LabMedica brings the latest in molecular genetics, cytogenetics, and epigenetics, and methods from PCR to FISH, and more.